Hashem Anas, Mohamed Mohamed Salah, Alabdullah Khaled, Elkhapery Ahmed, Khalouf Amani, Saadi Samer, Nayfeh Tarek, Rai Devesh, Alali Omar, Kinzelman-Vesely Elissa A, Parikh Vishal, Feitell Scott C
Internal Medicine Resident, Rochester General Hospital, Rochester, NY.
Internal Medicine Resident, Rochester General Hospital, Rochester, NY.
Curr Probl Cardiol. 2023 Jun;48(6):101658. doi: 10.1016/j.cpcardiol.2023.101658. Epub 2023 Feb 23.
Cardiac arrest (CA) is associated with high mortality rate, ranging between 75% and 93%. Given its significance, venoarterial extracorporeal membrane oxygenation (VA-ECMO) has been used for end-organs perfusion and to maintain adequate oxygenation as a life-saving option in refractory CA. The predictors for the success of VA-ECMO in this setting have not been established yet. In this meta-analysis, we aim to identify the variables associated with increased mortality in patients with CA supported with VA-ECMO. We conducted a systematic review and meta-analysis to evaluate mortality-predicting factors in patients with CA supported with VA-ECMO that were published between January 2000 and July 2022. To identify relevant articles, the MEDLINE (Pubmed, Ovid) and Cochrane Databases were queried with various combinations of our prespecified keywords, including VA-ECMO, CA, and mortality predictors. We performed a meta-analysis using a random-effects model to calculate the odds ratio (OR). We retrieved a total of 4476 records, out of which we included 10 observational studies in our study. A total of 931 patients were included in our study with the age range of 47-68 years, predominantly males (63.9%). The overall mortality was 69.4%. The predictors for mortality were age >65 (OR 4.61, 95% CI 1.63-13.03, P < 0.01), history of chronic kidney disease (OR 2.42, 95% CI 1.37-4.28, P < 0.01), cardiopulmonary resuscitation duration prior to ECMO > 40 minutes (OR 6.62 [95% CI 1.39, 9.02], P < 0.01), having an initial nonshockable rhythm (OR 2.62 [95% CI 1.85, 3.70], P < 0.01) and sequential organ failure assessment score >14 (OR 12.29, 95% CI 2.71-55.74, P <0.01). Regarding blood work, an increase in lactate by 5 mmol/L increased the odds of mortality by 121% (2 studies; OR 2.21 [95% CI 1.26, 3.86], P < 0.01; I2 = 0%) while the increase in lactate by 1 mmol/L increases odd of mortality by 15% (2 studies, OR 1.15 [95% CI 1.02, 1.31], P = 0.03, I = 0%), and an increase in creatinine by 1 mg/dL increased the odds of mortality by 225% (1 study; OR 3.25 [95% CI 1.22, 8.7], P = 0.02). Albumin was protective as for each 1 g/dL increase, the odds of mortality decreased by 68% (1 study; OR 0.32 [95% CI 0.14, 0.74], P < 0.01). Refractory CA requiring VA-ECMO has a high mortality. Predictors of mortality include age >65, history of chronic kidney disease, cardiopulmonary resuscitation duration prior to ECMO > 40 minutes, initial rhythm being non-shockable and Sequential Organ Failure Assessment score >14.
心脏骤停(CA)的死亡率很高,在75%至93%之间。鉴于其严重性,静脉-动脉体外膜肺氧合(VA-ECMO)已被用于终末器官灌注,并作为难治性CA的一种挽救生命的选择来维持充足的氧合。在这种情况下,VA-ECMO成功的预测因素尚未确定。在这项荟萃分析中,我们旨在确定与接受VA-ECMO支持的CA患者死亡率增加相关的变量。我们进行了一项系统评价和荟萃分析,以评估2000年1月至2022年7月发表的接受VA-ECMO支持的CA患者的死亡率预测因素。为了识别相关文章,我们使用预先指定的关键词(包括VA-ECMO、CA和死亡率预测因素)的各种组合在MEDLINE(PubMed、Ovid)和Cochrane数据库中进行检索。我们使用随机效应模型进行荟萃分析以计算比值比(OR)。我们总共检索到4476条记录,其中我们在研究中纳入了10项观察性研究。我们的研究共纳入931例患者,年龄范围为47 - 68岁,以男性为主(63.9%)。总体死亡率为69.4%。死亡率的预测因素包括年龄>65岁(OR 4.61,95%CI 1.63 - 13.03,P < 0.01)、慢性肾病病史(OR 2.42,95%CI 1.37 - 4.28,P < 0.01)、ECMO前心肺复苏持续时间>40分钟(OR 6.62 [95%CI 1.39,9.02],P < 0.01)、初始心律不可电击复律(OR 2.62 [95%CI 1.85,3.70],P < 0.01)以及序贯器官衰竭评估评分>14(OR 12.29,95%CI 2.71 - 55.74,P <0.01)。关于血液检查,乳酸增加5 mmol/L使死亡几率增加121%(2项研究;OR 2.21 [95%CI 1.26,3.86],P < 0.01;I2 = 0%),而乳酸增加1 mmol/L使死亡几率增加15%(2项研究,OR 1.15 [95%CI 1.02,1.31],P = 0.03,I = 0%),肌酐增加1 mg/dL使死亡几率增加225%(1项研究;OR 3.25 [95%CI 1.22,8.7],P = 0.02)。白蛋白具有保护作用,每增加1 g/dL,死亡几率降低68%(1项研究;OR 0.32 [95%CI 0.14,0.74],P < 0.01)。需要VA-ECMO的难治性CA死亡率很高。死亡率的预测因素包括年龄>65岁、慢性肾病病史、ECMO前心肺复苏持续时间>40分钟、初始心律不可电击复律以及序贯器官衰竭评估评分>14。